Malaria mortality remains highly seasonal in rural Burkina Faso.
The WHO recommends that children living in areas of highly seasonal malaria transmission in the Sahel subregion should receive seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine plus amodiaquine (SPAQ).
A pilot study to test the efficacy of combining an organophosphate-based insecticide paint and pyrethroid-treated Long Lasting Insecticide Treated Nets (LLINs) against pyrethroid-resistant malaria vector mosquitoes was performed in a real village setting in Burkina Faso.
These ex vivo results suggest that treatment with the currently available artemisinin-based combinations is efficacious for the treatment of malaria in pregnancy in Burkina Faso.
Prior to a chimpanzee adenovirus-based (ChAd63) malarial vaccine trial, sera were collected to assess ChAd63-specific neutralizing antibody titers in Banfora (Burkina Faso).
The increase in molecular markers linked with SP resistance jeopardises the efficacy of IPTp and the planned IPTi interventions in Burkina Faso, calling for careful monitoring of genotypic resistance markers and in vivo validation of IPT efficacy.
Both Kiribina and Folonzo chromosomal forms are formidable malaria vectors in Burkina Faso.
The molecular form composition of Anopheles gambiae Giles s.s. (Diptera: Culicidae) mating swarms and the associated mating pairs (copulae) were investigated during two rainy seasons (July to October, 2005 and July to November, 2006) in the villages of Soumousso and Vallée du Kou (VK7).
These data confirm previously reported differences in P. falciparum susceptibility between Fulani and Mossi.
A 26-year-old, gravida 1, para 0, 37-week-pregnant immigrant from Burkina Faso presented with a 1-week history of intermittent fevers, headache, and myalgia. She had a past medical history of malaria (10 years before admission) in Burkina Faso, where she most recently visited on a 2-week trip about 2 months prior to admission.